bca101,pembrolizumab
bicara,merck
['headandneck', 'bca101', 'hanna', 'bicara', 'cara thera']
today at the #asco23 annual meeting dr. glenn hanna presents exciting interim data from bicara s open-label phase 1/1b dose expansion study of bca101, demonstrating clinically meaningful activity among front-line r/m hnscc. #headandneckcancer 
Clinical stage biotech developing biologics that combine targeted therapy & immunotherapy to provide meaningful & safer therapies to cancer patients